arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Merck & Co., Inc.

MRK
$148.10 ▼ -3.03 (-2.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
75 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Bullish
auto_awesome

Analytical Summary

Merck & Co., Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $365.8B
Dividend Yield 0.57%
Revenue Growth 5.1%
Op. Margin
ROIC
FCF / Share $1.81
Trailing P/E
Price / Book 8.7x
FCF Yield 1.2%
Debt / Equity 1.22
info Valuation on last close. End-of-day price, Sep 23, 2026.

75-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$16.61B
↑ +5.1%
Net Income Profit after all expenses
$-1.33B
↑ +68.5%
FCF / Share Free cash flow per share
$1.81
↑ +53.1%
Long-Term Debt Long-term obligations
$51.08B
↑ +9.4%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
85
Returns
94
Financial Health
32
Cash Quality
47

Dividend History

Dividend / share · sourced from SEC filings
$3.28 Latest / share
+5.1% YoY
+5.8% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 20 years · 75 quarters